Pasithea Therapeutics (KTTA) Cash from Financing Activities (2021 - 2026)
Pasithea Therapeutics (KTTA) posted Cash from Financing Activities of $750.0 for Q1 2026, down 100.0% sequentially from $56.4 million in Q4 2025, and down 99.95% YoY from $1.5 million in Q1 2025.
Pasithea Therapeutics (KTTA) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Cash from Financing Activities for 5 years, with the latest figure at $750.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 99.95% year-over-year to $750.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62.0 million (up 2675.57% YoY) and the FY2025 annual result came in at $63.5 million, up 1306.02% from the prior year.
- Cash from Financing Activities retreated to $750.0 in Q1 2026 per KTTA's latest filing, from $56.4 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $56.4 million in Q4 2025 and troughed at -$3.9 million in Q3 2023.
- A 4-year average of $6.6 million and a median of $750.0 in 2026 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities jumped 239682.21% in 2025, then tumbled 99.95% in 2026.
- Over 4 years, Cash from Financing Activities stood at -$3.9 million in 2023, then surged by 99.39% to -$23550.0 in 2024, then surged by 239682.21% to $56.4 million in 2025, then plunged by 100.0% to $750.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $750.0, $56.4 million, and -$116145.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - | 8,476.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 750.00 |
| Mar 31, 2026 | 750.00 |
| Dec 31, 2025 | 56.42 Mn |
| Dec 31, 2025 | 56.42 Mn |
| Sep 30, 2025 | -116,145.00 |
| Sep 30, 2025 | -116,145.00 |
| Jun 30, 2025 | 5.74 Mn |
| Jun 30, 2025 | 5.74 Mn |
| Mar 31, 2025 | 1.47 Mn |
| Mar 31, 2025 | 1.47 Mn |
| Dec 31, 2024 | -23,550.00 |
| Dec 31, 2024 | -23,550.00 |
| Sep 30, 2023 | -3.86 Mn |
| Sep 30, 2023 | -3.86 Mn |
| Jun 30, 2023 | -130,768.00 |
| Jun 30, 2023 | -130,768.00 |
| Mar 31, 2023 | 264,103.00 |
| Mar 31, 2023 | 264,103.00 |
| Dec 31, 2021 | 34.17 Mn |
| Dec 31, 2021 | 34.17 Mn |